Belite Bio, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
BLTE
Belite Bio, INCYu-Hsin Lin, CEO and Chairman of Belite Bio, Inc., has filed a Schedule 13G, reporting beneficial ownership of 3.1% of the company's ordinary shares as of March 31, 2026.
NASDAQ
BLTE
Belite Bio, INCSCHEDULE 13G: Darwin Global Discloses 7.0% Stake in Belite Bio
Darwin Global Management, Ltd., along with its Master Fund and CIO Dr. Abhishek Trehan, has disclosed a beneficial ownership of 7.0% in Belite Bio, Inc.'s ordinary shares.
NASDAQ
BLTE
Belite Bio, INCYu-Hsin Lin, CEO and Chairman of BELITE BIO, INC., has reported a beneficial ownership of 7.1% of the company's ordinary shares as of December 31, 2024, through a Schedule 13G filing.
NASDAQ
BLTE
Belite Bio, INCLin Bioscience International Ltd. has reported a beneficial ownership of 53.7% in Belite Bio, Inc., making it a majority shareholder.